Your browser doesn't support javascript.
loading
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.
Hashemi-Meshkini, Amir; Zekri, Hedieh Sadat; Karimi-Yazdi, Hasan; Zaboli, Pardis; Sahraian, Mohammad Ali; Nikfar, Shekoufeh.
Affiliation
  • Hashemi-Meshkini A; Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Zekri HS; Department of Health Economics and Management, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Karimi-Yazdi H; School of Medicine, Qom University of Medical Sciences, Qom, Iran.
  • Zaboli P; Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Nikfar S; Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Neurol ; 17(3): 123-128, 2018 Jul 06.
Article in En | MEDLINE | ID: mdl-30886679
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Iran J Neurol Year: 2018 Document type: Article Affiliation country: Iran Country of publication: Iran
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Iran J Neurol Year: 2018 Document type: Article Affiliation country: Iran Country of publication: Iran